400 3RP (Ribasphere 400 mg)
Generic Name: ribavirin
This pill with imprint "400 3RP" is Blue, Elliptical / Oval and has been identified as Ribasphere 400 mg. It is manufactured by Three Rivers Pharmaceuticals, LLC.
Ribasphere is used in the treatment of hepatitis c and belongs to the drug classes inhaled anti-infectives, purine nucleosides. Not for use in pregnancy. Ribasphere 400 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- ribavirin
- Imprint:
- 400 3RP
- Strength:
- 400 mg
- Color:
- Blue
- Size:
- 18.00 mm
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- Inhaled anti-infectives
Purine nucleosides - Pregnancy Category:
- X - Not for use in pregnancy
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Three Rivers Pharmaceuticals, LLC
- National Drug Code (NDC):
- 66435-0103
- Inactive Ingredients:
- microcrystalline cellulose
lactose monohydrate
croscarmellose sodium
povidone
magnesium stearate
water
polyvinyl alcohol
titanium dioxide
polyethylene glycol 3350
magnesium silicate
FD&C Blue No. 1
carnauba wax
Note: Inactive ingredients may vary.
| NDC Code | Manufacturer / Repackager |
|---|---|
| 66435-0105 | Three Rivers Pharmaceuticals, LLC |
| 00074-3239 | Abbott Laboratories |
More about Ribasphere (ribavirin)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 1 Review – Add your own review/rating
- Drug class: inhaled anti-infectives
Consumer resources
Other brands: Rebetol, Copegus, Virazole, RibaTab, More... (2)
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
